Table 4 Clinical PET studies using
Radioconjugate and Year | Study | No Participants | Outcome | References |
|---|---|---|---|---|
[18F]AlF-PSMA-BCH (2019) | Newly diagnosed prostate cancer (PCa) | 11 | Tumours identified | Liu et al. (2019) |
[18F]AlF-PSMA-11 (2019) | Dosimetry and biodistribution in PCa | 6 | Radioconjugate can be safely administered with a mean effective dose of 12.8 ± 0.6 µSv/MBq, similar to [18F]DCFPyL | Piron et al. (2019) |
[18F]AlF-PSMA-11 (2020) | Optimisation of PET protocols for PCa | 44 | 2.0 ± 0.2 MBq/kg identified as the preferred dose. Diuretic can be useful for lesions in proximity to the ureters | Piron et al. (2020b) |